(-0.19%) 5 459.02 points
(-0.35%) 38 975 points
(0.07%) 17 730 points
(0.36%) $81.12
(-3.48%) $2.66
(-0.96%) $2 308.40
(-0.43%) $28.75
(1.48%) $1 001.00
(0.29%) $0.936
(0.73%) $10.68
(0.40%) $0.791
(-0.07%) $87.43
Live Chart Being Loaded With Signals
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States...
Stats | |
---|---|
本日の出来高 | 68 834 |
平均出来高 | 0 |
時価総額 | 0.00 |
EPS | $-0.320 ( Q1 | 2022-04-27 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.950 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0320 (1.46%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-07-08 | Innoviva Strategic Opportunities Llc | Buy | 7 598 814 | Common Stock |
2022-07-07 | Tommasi Ruben | Sell | 39 596 | Common Stock |
2022-07-11 | Tommasi Ruben | Sell | 150 000 | Common Stock |
2022-07-11 | Tommasi Ruben | Sell | 98 700 | Stock Option (right to buy) |
2022-07-11 | Tommasi Ruben | Sell | 50 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
52.71 |
Last 98 transactions |
Buy: 9 607 238 | Sell: 3 128 729 |
ボリューム 相関
Entasis Therapeutics 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Entasis Therapeutics 相関 - 通貨/商品
Entasis Therapeutics 財務諸表
Annual | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.996 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.996 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.10 |
FY | 2019 |
収益: | $7.00M |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.33 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Entasis Therapeutics
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。